NZ720887A - Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide - Google Patents

Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide

Info

Publication number
NZ720887A
NZ720887A NZ720887A NZ72088714A NZ720887A NZ 720887 A NZ720887 A NZ 720887A NZ 720887 A NZ720887 A NZ 720887A NZ 72088714 A NZ72088714 A NZ 72088714A NZ 720887 A NZ720887 A NZ 720887A
Authority
NZ
New Zealand
Prior art keywords
crystalline forms
hcv
macrocyclic hcv
tripeptide
inhibiting
Prior art date
Application number
NZ720887A
Other languages
English (en)
Inventor
Dustin Bringley
Peter Fung
Katie Keaton
Olga Lapina
Henry Morrison
Johann Chan
Dominika Pcion
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NZ720887A publication Critical patent/NZ720887A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
NZ720887A 2013-12-23 2014-12-18 Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide NZ720887A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920427P 2013-12-23 2013-12-23
PCT/US2014/071310 WO2015100144A1 (en) 2013-12-23 2014-12-18 Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide

Publications (1)

Publication Number Publication Date
NZ720887A true NZ720887A (en) 2018-01-26

Family

ID=52282995

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ720887A NZ720887A (en) 2013-12-23 2014-12-18 Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide

Country Status (12)

Country Link
US (2) US9562058B2 (enExample)
EP (1) EP3087086B1 (enExample)
JP (2) JP6568541B2 (enExample)
AR (1) AR098958A1 (enExample)
AU (1) AU2014370124A1 (enExample)
CA (1) CA2934049A1 (enExample)
ES (1) ES2708993T3 (enExample)
NZ (1) NZ720887A (enExample)
PT (1) PT3087086T (enExample)
TW (1) TW201609752A (enExample)
UY (1) UY35918A (enExample)
WO (1) WO2015100144A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2934537C (en) * 2013-12-23 2022-08-16 Gilead Sciences, Inc. Synthesis of an antiviral compound
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JOP20170127A1 (ar) * 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
CN115417803B (zh) * 2022-08-30 2023-10-03 四川同晟生物医药有限公司 乌帕替尼中间体(3r,4s)-1-苄氧羰基-4-乙基吡咯烷-3-羧酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
ES2392611T3 (es) * 2008-07-22 2012-12-12 Merck Sharp & Dohme Corp. Compuestos de quinoxalina macrocíclica como inhibidores de la proteasa NS3 del VHC
TWI523658B (zh) * 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之ｈｃｖ絲胺酸蛋白酶抑制劑
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US20130164260A1 (en) 2011-11-16 2013-06-27 Gilead Sciences, Inc. Antiviral compounds
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с

Also Published As

Publication number Publication date
US9562058B2 (en) 2017-02-07
JP2017503016A (ja) 2017-01-26
AR098958A1 (es) 2016-06-22
EP3087086A1 (en) 2016-11-02
US20170267694A1 (en) 2017-09-21
US9862728B2 (en) 2018-01-09
UY35918A (es) 2015-05-29
US20150175625A1 (en) 2015-06-25
PT3087086T (pt) 2019-02-06
EP3087086B1 (en) 2018-11-07
JP6568541B2 (ja) 2019-08-28
CA2934049A1 (en) 2015-07-02
ES2708993T3 (es) 2019-04-12
AU2014370124A1 (en) 2016-06-23
TW201609752A (zh) 2016-03-16
JP2019089819A (ja) 2019-06-13
WO2015100144A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
WO2013059530A3 (en) Peptidomimetic macrocycles
EP3040193A4 (en) Waterproof breathable membrane, waterproof breathable component provided with same, waterproof breathable structure, and waterproof sound-permeable membrane
EP2279227A4 (en) ANIONIC LATEX AS VEHICLE OF ACTIVE INGREDIENTS AND METHODS OF MAKING AND USING THE SAME
WO2018098282A3 (en) Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
HK1205454A1 (en) Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
HK1202549A1 (en) Donepezil pamoate, preparation method and its use
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX2014003180A (es) Metodos para tratar vhc.
MX362489B (es) Inhibidores dipeptídicos y tripeptídicos de epoxi cetona proteasa.
WO2015058132A3 (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses
EP2112907A4 (en) PEARL FOR SEWING, VACUUM CAP FOR SUCKING AN INNER ORGAN AND DEVICE FOR SEWING AN INNER ORGAN
EP3087093A4 (en) Pharmaceutically relevant aromatic-cationic peptides
HK1231493A1 (zh) 药学上相关的芳香族阳离子肽
MY165041A (en) Composition for improving brain function and method for improving brain function
NZ749998A (en) Tfpi inhibitors and methods of use
UY35918A (es) Formas cristalinas de un compuesto antiviral
EP3225627A4 (en) Tripeptide compound, preparation method therefor, and application thereof
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer
MX368628B (es) Tripeptidos antiinflamatorios.
EP2039708A4 (en) CYCLOOLEFIN ADDITIVE COPOLYMER, PREPARATION METHOD AND COPOLYMER RECEIVED DELAYING FILM
EP3638280A4 (en) PEPTIDES AND USES THEREOF AS VIRUCIDES
EP3904367A4 (en) TETRAPEPTIDE COMPOUND, METHOD FOR PREPARATION AND USE
HK1224304A1 (zh) 用於治療嚴重低血糖的新穎的化合物
HK1224303A1 (zh) 用於治療嚴重低血糖的新穎的化合物

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed